Biologics Issues and stabilisation Flashcards

1
Q

For mAbs and other therapeutic proteins in solution, the hydrophobic AA should be buried in the __a__ and the hydrophilic AA should be in the __b__ .

A

a) Protein core
b) shell

Hydrophobic = non polar, aliphatic side groups, aromatic side chains

Hydrophillic = polar uncharged side groups, polar charged, negatively charged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Most likely to have non polar groups __A__ protein. Hydrophillic groups most likely to be on __B__.

A

a) inside

b) outside

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does the presence of salt bridges do to the conformation of the protein?

A

The presence of salt bridges “rigidifies” the conformation (can still move)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Consequences of unfolding of protein?

A
  • Unfolding (denaturation or exposure of hydrophobic core) may lead to aggregation.
  • Protein is a mix of various systems.
  • If the integrity is altered, It can unfold and lead to denaturation and lead to exposure to hydrophobic core.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

are mAbs colloids?

A

• mAbs (and other proteins) are not colloids

▫ Not a uniform distribution of the same charge (there is a variation of charges)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How to stabilise biologics?

A

• Need to consider attractive and repulsive forces but also hydrophobicity
▫ And consequently pH, buffer, salt (concentration and type) and concentration of co-solutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Examples of stresses that can lead to a change in ;conformation of protein:

A

Changes in pH, T, p, ionic strength, concentration of co-solutes all can result in unfolding the protein thus ultimately aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Increasing T or p=

A

Increased movement of protein and favours unfolding

Reduces reversible aggregation in favour of irreversible aggregation (something you really want to avoid).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Decreasing T ____ rate of aggregation:

A

Decreases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pressure if extremely important when considering biologics as:

A

most of the proteins will be injected which requires pressure on syringe = sheer force which can potentially unfold protein.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Influence of pH on aggregator?

A

• Changing pH alters the charge of the protein and increasing ionic strength results in electrostatic forces to be felt a short distances
▫ Shifts of pH towards isoelectric point or high ionic strength tend to favour aggregation because you have a particle which isn’t charged.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Examples of chemical degradation:

A

Oxidation, deamidation, hydrolysis
May lead to instability then aggregation
- Exposure hydrophobic regions (will try to avoid contact with water)
- Exposure of cysteine residues of formation of disulfide bridges

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Examples of physical destabilisation:

A
▫ Extreme pH
▫ Shear forces, (pressure you put on the plunger of syringe when you inject)
▫ Air-water interfaces
▫ Adsorption to solid surfaces
▫ Freezing drying
▫ High pH or T
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is preferential binding?

A

Preferential binding = co solute will bind to the surface of your protein and this will have an effect.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is preferential exclusion?

A

Preferential exclusion of co-solute: co-solute mainly out of the solvation shell of the protein. Could increase the chemical potential of the unfolding protein interface.
which increases the thermodynamic stability of the native protein relative to the unfolding larger difference energy makes it less likely to unfold and lead to aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Preferential interaction example:

A

Denaturant: interaction with backbone of protein e.g. urea H-bonding with most AA side chains

17
Q

How does sucrose work as a protectant (preferential exclusion)

A

Lower interaction with protein but not hydrophobic leads to higher concentration of co-solute in bulk (and will attract the water) than in the solvation shell of the protein. Makes it shrink, tighter and less likely to unfold

18
Q

Stabilisation mechanism of amino acids:

A

Preferential hydration, preferential exclusion, decrease protein protein interactions, increase solubility, reduce viscosity

19
Q

Stabilisation mechanism of polymers:

A

Competitive absorption, steric exclusion, preferential exclusion, preferential hydration

20
Q

Stabilisation mechanism of surfactants:

A

Competitive absorption at interfaces, reduces denaturation at air/water interfaces

21
Q

How does acylation work in terms of stabilising proteins?

A

Acylation with fatty acid to increase binding affinity tp serum albumin resulting in longer acting insulin, glucagon and interferon

22
Q

How does PEGylation work in terms of stabilising proteins?

A

To reduce plasma clearance rate and achieve less frequent admin. However, some binding proteins less active when PEGylated

23
Q

Stability testing for biologics is defined in the:

A

ICHQ5C

24
Q

How is shelf life determined?

A

during long term stability (real time/real temperature data)

25
Q

What are accelerated studies?

A

▫ Support to establish the shelf life
▫ Provide info on changes, validation of stability tests
▫ Generate help to understand degradation profiles
▫ Test conditions are normally done earlier than real storage conditions

26
Q

Summary of conditions for long term, accelerated and stress studies:

A
Long term:
20 degrees (+-5)
5 degrees (+-3)
25 degrees (+-2) / 60% RH

Accelerated:
5 degrees
25 degrees/ 60% RH
40 degrees 75% RH

Stress:
Temp, pH, light, oxidation, shaking, freeze thaw

27
Q

Long term testing duration:

A

Guidance is 0.5 – 5 years shelf life for most biologicals:

< 1 year shelf life = monthly for the first 3 months and 3 month interval thereafter

> 1 year shelf life = every 3 months during first year, every 6 months during second year, annually thereafter

28
Q

Issues with freezing and lyophilisation:

A
  • Low temperature extend shelf life of medicine but cold denaturation which happens when freezing sample may lead to damage as freezing results in change of pH, ionisation, solubility or H-bond energies.
    • Repeated freezing and thawing cause aggregation by pH and concentration changes and by provision of nucleation points at ice water interface
    • Cryoprotection by sugars, polyhydric alcohols, AAs, work by preferential exclusion, lower cold denaturation and stabilise sample

Slow cooling = large crystals

29
Q

Issues with freezing?

A

Much more protein in centre compared to side

Cold comes from outside, water molecules will freeze more quickly which will leave what is left more concentrated and will be much more based in the centre of product

30
Q

Lyophilised (freeze dried) protein formulations have a ____ long term stability.

A

Greater

31
Q

Process of freeze drying:

A

▫ Freeze: product is completely frozen in a vial
▫ Vaccum: product is placed under deep vacuum well below triple point of water
▫ Dry: heat energy is added causing ice to sublime

32
Q

Do any conformational changes take place during the different steps of lyophilisation:

A
  • These do undergo reversible conformational changes during the different steps of lyophilisation with render them prone to aggregation (and similarly again when reconstituted).
  • Reactions and denaturation continue when lyophilised.
33
Q

How to overcome aggregation in lyophilised biologics:

A

▫ Refrigerate lyophilised medicines to reduce aggregation rates
▫ Hygroscopic – sealed to avoid water vapour absorption